Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia

References

• Bloomfield C D, Shuma C, Regal L, Philip P P, Hossfeld D K, Hagemeijer A M, Garson O M, Peterson B A, Sakurai M, Alimena G, Berger R, Rowley J D, Ruutu T, Mitelman F, Dewald G W, Swansbury J. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80(Suppl 11)2191–2198
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969–2977
   PubMed Web of Science ®Google Scholar
• Mandelli F, Petti M C, Lo Coco F. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. Haematologica 1998; 83(11)1015–1023
   PubMedGoogle Scholar
• Marie J P, Zittoun R, Sikic B I. Multidrug resistance (mdr 1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Wood P, Burgess R, MacGregor A, Yin J. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. British Journal of Haematology 1994; 87: 509–514
   PubMed Web of Science ®Google Scholar
• Lamy T, Goasguen J E, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, le Prise P Y. P-glycoprotein (p-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994; 8: 1879–1883
   PubMed Web of Science ®Google Scholar
• Damiani D, Michieli M, Ermacora A, Candoni A, Raspadori D, Geromin A, Stocchi R, Grimaz S, Masolini P, Michelutti A, Scheper R J, Baccarani M. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 1998; 83: 290–297
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper R J, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non lymphocytic leukemias: biological and clinical implications. British Journal of Haematology 1999; 104: 328–335
   PubMed Web of Science ®Google Scholar
• Raspadori D, Lauria F, Ventura M A, Rondelli D, Visani G, de Vivo A, Tura S. Incidence and prognostic relevance of CD34 expression in acute myeloblasts leukemia: analysis of 141 cases. Leukemia Research 1997; 21: 603–607
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault J P, Sabido O, Oriol P, Roubi N, Vasselan C, Archimbaud E. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Maung Z T, McLean F R, Reid M M, Pearson A DJ, Proctor Sj, Hamilton P J, Hall A G. The relationship between bcl-2 expression and the response to chemotherapy in acute leukemia. British Journal of Haematology 1994; 88: 105–109
   PubMed Web of Science ®Google Scholar
• Lauria F, Raspadori D, Rondelli D, Ventura M A, Fiacchini M, Visani G, Forconi F, Tura S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11: 2075–2078
   PubMed Web of Science ®Google Scholar
• Kasimir-Bauer S, Ottinger H, Meusers P, Beelen D W, Brittinger G, Seeber S, Scheulen M E. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance related protein, bcl-2, and the heat shock protein 27, is predictive of the response to induction chemotherapy. Experimental Hematology 1998; 26(12)1111–1117
   PubMed Web of Science ®Google Scholar
• Karakas T, Maurer U, Weidman E, Miething C C, Hoelzer D, Bergman L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Annals of Oncology 1998; 9: 159–165
   PubMed Web of Science ®Google Scholar
• Zittoun R A, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with the intensive consolidation chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995; 332: 217–227
   PubMed Web of Science ®Google Scholar
• Gale R P, Buchner T, Zhang M -J, Heinecke A, Champlin R E, Dicke K A, Gluckman E, Gratwohl A, Herzig R H, Keating A, Klein J P, Marmont A M, Prentice H G, Rowlings P A, Sobocinski K A, Speck B, Weiner R S, Horowitz M M. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia 1996; 10: 1687–1691
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, Willman C, Hurd D D, Bennet J M, Blume K G, Head D R, WierniK P H. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the managment of acute myeloid leukemia in first remission. New England Journal of Medicine 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Leith C, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, Head D R, Appelbaun E R, William C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Chen I M, Eijdems L, Slovak M L, McConnell T, Head D R, Weick J, Grever M R, Appelbaun E R, William C L. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086–1099
   PubMed Web of Science ®Google Scholar
• Gekeler V, Frese G, Noller A, Handgretinger R, Wilish A, Schmidt H, Muller C P, Dopfe R, Keingebiel T, Diddens H, Probst H, Niethammer D. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase gene expression in primary and relapsed state adult and childhood leukaemias. British Journal of Cancer 1992; 66: 507–517
   PubMed Web of Science ®Google Scholar
• Russo D, Marie J P, Zhou D C, Faussat A M, Delmer A, Maisonneuve L, Hoang Ngoc L, Baccarani M, Zittoun R. Coexpression of anionic glutathione-S-transferase (GST) and multidrug resistance (mdrl) genes in acute myeloid and lymphoid leukemias. Leukemia 1994; 8: 881–884
   PubMed Web of Science ®Google Scholar
• Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3273
   PubMed Web of Science ®Google Scholar
• Michieli M, Michelutti A, Damiani D, Pipan C, Raspadori D, Lauria F, Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia and Lymphoma 1993; 9: 255–264
   PubMed Web of Science ®Google Scholar
• Tallman M S, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474
   PubMed Web of Science ®Google Scholar
• Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R, Baccarani M. Effect of fludarabine and arabinosylcytosine on multidrug resistan cells. Haematologica 1997; 82: 143–147
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Keating M J, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Seymour J F, Peng H, Plunkett W, Gandhi V. Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a Continous Infusion Schedule. Clinical Cancer Research 1996; 2: 653–658
   PubMed Web of Science ®Google Scholar
• Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani P L, Tura S. Fludarabine+Ara-C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8: 2076–2082
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Gandhi V, Rios M B, Kantarjian H, Keating M J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia and Lymphoma 1993; 9: 343–350
   PubMed Web of Science ®Google Scholar
• Estey E H, Thall P F, Pierce S, Cortes J, Beran M, Kantarjian H, Keating M J, Andreeff M, Freireich E. Randomized phase II study of Fludarabine + Cytosine Arabinoside + Idarubicin +/- All-trans retinoic acid +/- granulocyte colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 8: 2478–2484
   Google Scholar
• Visani G, Tosi P, Zinzani P L, et al. FLAG (Fludarabine+high-dose cytarabine+G-CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemias. Leukemia 1994; 8: 1842–46
   PubMed Web of Science ®Google Scholar
• Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti A M, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M. High efficacy of fludarabine-containing therapy (FLAG-FLANG) on poor risk acute myeloid leukemia. Haematologica 1996; 81: 513–520
   PubMed Web of Science ®Google Scholar
• Huhmann I M, Watzke H H, Geissler K, Gisslinger H, Jäger U, Knöbl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas O A, Lechner K. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Annals of Hematology 1996; 73: 265–271
   PubMed Web of Science ®Google Scholar
• Montillo M, Mirto S, Petti M C, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. American Journal of hematology 1998; 58: 105–109
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology 1997; 96: 356–365
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. Journal American Statistic Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Kolbfliesh J D, Prentice R L. The statistical analysis of failure time data. Wiley, New York, NY 1980
   Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G. Design and analysis of randomized clinical trials required prolonged observation of each patient. II. Analysis and example. British Journal of Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox D R. The Analysis of Bynary Data. Chapman & Hall, London 1970
   Google Scholar
• Wiernik P H, Banks P LC, Case D C, Arlin Z A, Periman P O, Todd M B, Ritch P S, Enck R E, Weitberg A B. Cytarabine plus Idarubicin oer Daunorubicin as induction and consolidation therapy for previously untreated adult patient with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig W D, Bartholomaus A, Bettlheim P, Wormann B, Buchner T, Hiddemann W, German AML Cooperative Group. Superiority of high-dose over intermediate-dose cytostne arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998; 12: 1049–1055
   PubMed Web of Science ®Google Scholar
• Muus P, Zittoun R, Mandelli F, De Witte T, Willemze R, Resegotti L, Ferrini Rossi P, Liso V, Hayat M, Keating S, Amadori S, Dardenne M, Vegna M L, Petti M C, Solbu G, Suciu S, Leukemia Cooperative Group of the EORTC and GIME. M. A. Randomized phase III study of induction (ICE vs MICE vs DCE) and intensive consolidation (IDIA vs NOVIA vs DIA), followed by stem cell transplantation in AML: presentation and preliminary results of ongoing AML-10 EORTC LCG/GIMEMA study. Proceedings 8th International Symposium on Autologous Marrow and Blood Transplantation, Karel A Dicke, Armand Keating. Carde Jennings Publishing Co. Ltd., 1997; 3–15
   Google Scholar
• Keating S, Zittoun R, Suciu S, Mandelli F, De Witte T, Amadori S, Resegotti L, Varet B, Archimbaud E, Fazi P, Dardenne M, Willemze R. Post-remission therapy for patients with AML in first CR in the AML-10 trial of EORTC LCG and GIMEMA. Blood 1998; 92(Suppl 1)2037, Abs
   Google Scholar
• Damiani D, Michieli M, Ermacora A, Russo D, Fanin R, Zaja F, Baraldo M, Pea F, Furlanut M, Baccarani M. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia 1998; 12: 1236–1240
   PubMed Web of Science ®Google Scholar
• Visani G, Lemoli R M, Tosi P, Martinelli G, Testoni N, Ricci P, Piccaluga P P, Pastano R, Leopardi G, Dizdari A, Motta M R, Rizzi S, Tura S. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients. British Journal of Haematology 1999; 105: 775–779
   PubMed Web of Science ®Google Scholar